Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 USD | +0.75% | -1.95% | -35.78% |
03-28 | Arcadia Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-28 | Transcript : Arcadia Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 47.38 | 34.03 | 23.07 | 6.678 | 3.475 | 2.739 | - |
Enterprise Value (EV) 1 | 47.38 | 34.03 | 23.07 | 6.678 | 3.475 | 2.739 | 2.739 |
P/E ratio | -1.21 x | -5.38 x | -1.51 x | -0.42 x | -0.28 x | -0.36 x | -0.44 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 40.5 x | 4.24 x | 3.4 x | 0.67 x | 0.65 x | 0.44 x | 0.34 x |
EV / Revenue | 40.5 x | 4.24 x | 3.4 x | 0.67 x | 0.65 x | 0.44 x | 0.34 x |
EV / EBITDA | -2.47 x | - | -0.67 x | -0.36 x | -0.25 x | -0.29 x | -0.35 x |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 216 | 336 | 555 | 616 | 1,110 | 1,363 | - |
Reference price 2 | 219.2 | 101.2 | 41.60 | 10.84 | 3.130 | 2.010 | 2.010 |
Announcement Date | 20-03-25 | 21-03-30 | 22-03-30 | 23-03-30 | 24-03-28 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | 1.169 | 8.034 | 6.78 | 9.956 | 5.33 | 6.225 | 8 |
EBITDA 1 | -19.19 | - | -34.48 | -18.34 | -13.65 | -9.496 | -7.89 |
EBIT 1 | -19.38 | -21.59 | -35.53 | -18.82 | -13.94 | -11.08 | -8.19 |
Operating Margin | -1,657.91% | -268.76% | -523.98% | -188.98% | -261.5% | -177.99% | -102.38% |
Earnings before Tax (EBT) 1 | -28.87 | -6.15 | -16.13 | -15.6 | -13.16 | -10.93 | -8.19 |
Net income 1 | -28.8 | -4.655 | -14.66 | -15.38 | -13.98 | -10.93 | -8.19 |
Net margin | -2,464.07% | -57.94% | -216.22% | -154.44% | -262.31% | -175.58% | -102.38% |
EPS 2 | -181.2 | -18.80 | -27.60 | -25.65 | -11.30 | -5.615 | -4.610 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 20-03-25 | 21-03-30 | 22-03-30 | 23-03-30 | 24-03-28 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 2.376 | 2.171 | 3.22 | 3.858 | 1.878 | 1 | 1.509 | 1.389 | 1.597 | 1.17 | 1.194 | 1.426 | 1.857 | 1.749 | 1.5 |
EBITDA 1 | -7.181 | -13.6 | -4.461 | -3.642 | -4.466 | -5.744 | -3.977 | -3.724 | -3.153 | -3.304 | -2.791 | -2.477 | -2.048 | -2.18 | -2.445 |
EBIT 1 | -7.485 | -13.8 | -4.623 | -3.783 | -4.556 | -5.83 | -4.048 | -3.791 | -3.242 | -3.364 | -3.106 | -2.869 | -2.552 | -2.553 | -2.52 |
Operating Margin | -315.03% | -635.84% | -143.57% | -98.06% | -242.6% | -583% | -268.26% | -272.93% | -203.01% | -287.52% | -260.24% | -201.26% | -137.45% | -145.97% | -168% |
Earnings before Tax (EBT) 1 | -2.835 | -9.556 | -4.61 | -3.797 | -2.876 | -4.315 | -9.384 | 0.819 | -2.484 | -2.616 | -3.081 | -2.824 | -2.51 | -2.516 | -2.52 |
Net income 1 | -2.175 | -9.282 | -4.488 | -3.777 | -2.867 | -4.244 | -9.384 | 0.823 | -2.567 | -2.853 | -3.081 | -2.824 | -2.555 | -2.516 | -2.52 |
Net margin | -91.54% | -427.54% | -139.38% | -97.9% | -152.66% | -424.4% | -621.87% | 59.25% | -160.74% | -243.85% | -258.15% | -198.11% | -137.59% | -143.83% | -168% |
EPS 2 | -4.000 | -17.20 | -8.000 | -6.800 | -4.800 | -6.050 | -10.86 | 0.6100 | -1.890 | -1.990 | -2.215 | -1.560 | -1.165 | -1.105 | -1.480 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 21-11-15 | 22-03-30 | 22-05-12 | 22-08-11 | 22-11-10 | 23-03-30 | 23-05-11 | 23-08-10 | 23-11-09 | 24-03-28 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 20-03-25 | 21-03-30 | 22-03-30 | 23-03-30 | 24-03-28 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.78% | 2.72M | |
+20.03% | 39.28B | |
-.--% | 11.24B | |
+5.87% | 7.61B | |
+0.48% | 6.52B | |
+0.39% | 6.05B | |
-1.79% | 5.78B | |
+38.21% | 5.45B | |
-14.87% | 5.36B | |
-18.93% | 4.35B |
- Stock Market
- Equities
- RKDA Stock
- Financials Arcadia Biosciences, Inc.